ArticleEuropean geriatric medicine2026
The combined association of STOPPFall medication use and orthostatic blood pressure abnormalities with future falls and fractures in community-dwelling older people.
Article in European geriatric medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSTOPPFall(Screening Tool of Older Persons Prescriptions in older adults with high fall risk) defines fall-risk-increasing drugs(FRIDs) associated with orthostatic hypotension(OH)/falls. This study assesses the association between the cumulative effect of STOPPFall medications and OH, on future falls/fractures, over 4-year follow-up among community-dwelling older people ≥ 65 years using The Irish Longitudinal Study on Ageing(TILDA) data.
methodsSTOPPFall medications were recorded at Wave1. Orthostatic blood pressure(BP) was measured by active stand using a Finometer at Wave1, recording delayed BP recovery(drop in systolicBP(sBP) ≥ 20 mmHg and/or diastolicBP ≥ 10 mmHg from baseline at 30 s post-stand) and "any OH"(same BP drop at any of 30,60,90,120 s post-stand). Falls/fractures were self-reported. Logistic regression models using interaction terms generated odds ratios(ORs) assessing the association between the interaction of STOPPFall medications and delayed BP recovery/any OH at baseline, and falls(including injurious/unexplained falls) and all fractures at follow-up.
results1390 participants were included, mean age at baseline 71.0 years, 51% female. One STOPPFall medication was prescribed in 27%(372/1390) participants, 11%(147/1390) were prescribed ≥ 2STOPPFall medications. Over 40% participants fell during follow-up(592/1390,42.6%), 12%(160/1390) sustained fractures. The cumulative effect of ≥ 2STOPPFall medications and delayed BP recovery was independently associated with all falls[OR1.93(95%CI1.04-3.59);p = 0.036], injurious falls[OR2.97(95%CI1.55-5.68);p = 0.001] and all fractures[OR3.50(95%CI1.66-7.41);p = 0.001]. Prescription of ≥ 2STOPPFall medications and any OH was independently associated with all falls[OR1.98(95%CI1.11-3.54);p = 0.021], injurious falls[OR2.25(95%CI1.21-4.20);p = 0.011] and all fractures[OR2.81(95%CI1.34-5.90);p = 0.006].
conclusionPrescription of ≥ 2 STOPPFall medications and delayed BP recovery, and prescription of ≥ 2 STOPPFall medications and any OH, was associated with all falls, injurious falls and all fractures. This highlights the importance of multidomain interventions during multifactorial falls assessments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.